Cargando…

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model

PURPOSE: The clinical efficacy of cancer peptide vaccine therapy is insufficient. To enhance the anti-tumor effect of peptide vaccine therapy, we combined this therapy with an anti-CD4 mAb (GK1.5), which is known to deplete CD4(+) cells, including regulatory T cells (Tregs). METHODS: To determine th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujinami, Norihiro, Yoshikawa, Toshiaki, Sawada, Yu, Shimomura, Manami, Iwama, Tatsuaki, Sugai, Shiori, Kitano, Shigehisa, Uemura, Yasushi, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600353/ https://www.ncbi.nlm.nih.gov/pubmed/28955856 http://dx.doi.org/10.1016/j.bbrep.2016.02.010

Ejemplares similares

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Development of antigen‐prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse
por: Charneau, Jimmy, et al.
Publicado: (2022)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
por: Mashima, Hiroaki, et al.
Publicado: (2020)

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
por: Ikarashi, Daiki, et al.
Publicado: (2020)

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Time-lapse imaging assay using the BioStation CT: A sensitive drug-screening method for three-dimensional cell culture
por: Sakamoto, Ruriko, et al.
Publicado: (2015)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy
por: Mashima, Hiroaki, et al.
Publicado: (2021)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer
por: Oka, Miho, et al.
Publicado: (2021)

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
por: SAWADA, YU, et al.
Publicado: (2014)

In Vitro Murine Leukemia Retroviral Integration and Structure Fluctuation of Target DNA
por: Tsuruyama, Tatsuaki, et al.
Publicado: (2012)

Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
por: Akazawa, Yu, et al.
Publicado: (2019)

Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
por: Aoki, Hiroyasu, et al.
Publicado: (2021)

An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity
por: Wang, Xinmin, et al.
Publicado: (2021)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
por: Kim, Youngji, et al.
Publicado: (2021)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
por: Ikarashi, Daiki, et al.
Publicado: (2021)

Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
por: Sakaguchi, Asumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1cfddgi8i9a4gkaco7ut565713